Sökning: WFRF:(Kirchheiner Julia) > A systematic review...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03119naa a2200517 4500 | |
001 | oai:DiVA.org:uu-151506 | |
003 | SwePub | |
008 | 110412s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1515062 URI |
024 | 7 | a https://doi.org/10.2217/pgs.10.742 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Verhoef, Talitha I4 aut |
245 | 1 0 | a A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. |
264 | 1 | b Future Medicine Ltd,c 2010 |
338 | a print2 rdacarrier | |
520 | a Anticoagulant therapy with coumarin derivatives is often sub- or supra-therapeutic, resulting in an increased risk of thromboembolic events or hemorrhage, respectively. Pharmacogenetic-guided dosing has been proposed as an effective way of reducing bleeding rates. Clinical trials to confirm the safety, efficacy and effectiveness of this strategy are ongoing, but in addition, it is also necessary to consider the cost-effectiveness of this strategy. This article describes the findings of a systematic review of published cost-effectiveness analyses of pharmacogenetic-guided dosing of coumarin derivatives. Similarities and differences in the approaches used were examined and the quality of the analyses was assessed. The results of the analyses are not sufficient to determine whether or not pharmacogenetic-guided dosing of coumarins is cost effective. More reliable cost-effectiveness estimates need to become available before it is possible to recommend whether or not this strategy should be applied in clinical practice. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng |
653 | a MEDICINE | |
653 | a MEDICIN | |
700 | 1 | a Redekop, William K4 aut |
700 | 1 | a Darba, Josep4 aut |
700 | 1 | a Geitona, Mary4 aut |
700 | 1 | a Hughes, Dyfrig A4 aut |
700 | 1 | a Siebert, Uwe4 aut |
700 | 1 | a de Boer, Anthonius4 aut |
700 | 1 | a Maitland-van der Zee, Anke-Hilse4 aut |
700 | 1 | a Barallon, Rita4 aut |
700 | 1 | a Briz, Montserrat4 aut |
700 | 1 | a Daly, Ann4 aut |
700 | 1 | a Haschke-Becher, Elisabeth4 aut |
700 | 1 | a Kamali, Farhad4 aut |
700 | 1 | a Kirchheiner, Julia4 aut |
700 | 1 | a Manolopoulos, Vangelis G4 aut |
700 | 1 | a Pirmohamed, Munir4 aut |
700 | 1 | a Rosendaal, Frits R4 aut |
700 | 1 | a van Schie, Rianne M F4 aut |
700 | 1 | a Wadelius, Miau Uppsala universitet,Klinisk farmakogenomik och osteoporos4 aut0 (Swepub:uu)miawadel |
710 | 2 | a Uppsala universitetb Klinisk farmakogenomik och osteoporos4 org |
773 | 0 | t Pharmacogenomics (London)d : Future Medicine Ltdg 11:7, s. 989-1002q 11:7<989-1002x 1462-2416x 1744-8042 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-151506 |
856 | 4 8 | u https://doi.org/10.2217/pgs.10.74 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy